Brief communication

Breast Cancer Research and Treatment

, Volume 12, Issue 3, pp 307-310

Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels

  • G. BertelliAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica
  • , P. PronzatoAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica
  • , D. AmorosoAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica
  • , M. P. CusimanoAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica
  • , P. F. ConteAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica
  • , G. MontagnaAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia MedicaIstituto Scientifico di Medicina Interna
  • , S. BertoliniAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia MedicaIstituto Scientifico di Medicina Interna
  • , R. RossoAffiliated withIstituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p<0.05).

Our results support the hypothesis of a partial agonist action of this antiestrogen, although general clinical practice suggests that tamoxifen-related thrombotic events are rare.

Key words

tamoxifen adjuvant endocrine therapy plasma lipids antithrombin III